{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:18:59Z","timestamp":1781828339776,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG"},{"name":"Onkovis GmbH"},{"name":"Roche Pharma AG"},{"name":"TEVA Deutschland GmbH"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.lungcan.2017.07.031","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T12:31:30Z","timestamp":1505219490000},"page":"216-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer \u2013 final results from the prospective German TLK cohort study"],"prefix":"10.1016","volume":"112","author":[{"given":"Ulla","family":"von Verschuer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Werner","family":"Tessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Binninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"J\u00e4nicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.07.031_bib0005","series-title":"Bericht zum Krebsgeschehen in Deutschland","author":"Robert-Koch-Institut","year":"2016"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0010","series-title":"SEER Cancer Statistics Review, 1975\u20132013","year":"2016"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0020","article-title":"Molecular profiling of lung cancer","author":"Lovly","year":"2016","journal-title":"My Cancer Genome"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0025","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0030","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0040","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0045","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11864-009-0085-5","article-title":"Cisplatin versus carboplatin in NSCLC: is there one best answer?","volume":"9","author":"Sanborn","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0055","first-page":"CD009256","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer","author":"de Castria","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0060","first-page":"9","article-title":"Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review","volume":"7","author":"Choua\u00efd","year":"2015","journal-title":"Clin. Outcomes Res. CEOR"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0065","series-title":"Cancer Chemotherapy and Biotherapy Principles and Practice","article-title":"Platinum analogues","author":"Reed","year":"2011"},{"issue":"Suppl. 7","key":"10.1016\/j.lungcan.2017.07.031_bib0070","first-page":"29","article-title":"Overall survival and sequential treatment of patients with advanced NSCLC in German outpatients centres\u2014data from the clinical TLK Registry","volume":"36","author":"Marschner","year":"2013","journal-title":"Onkologie"},{"issue":"Suppl. 6","key":"10.1016\/j.lungcan.2017.07.031_bib0075","first-page":"153","article-title":"The treatment of lung cancer in German outpatient centres. Data from a clinical registry\u2014TLK Registry","volume":"34","author":"Tessen","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0080","unstructured":"F. Griesinger, M. Sebastian, N. Marschner, L. Spring, J. Sahlmann, A. Hipper, A. Karatas, A. Fleitz, M. J\u00e4nicke, W. Eberhardt, M. Thomas, Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): a non-interventional, prospective, multi-centre German Registry in Stage IIIb and IV NSCLC (AIO-TRK-0315), (submitted)."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"1994","key":"10.1016\/j.lungcan.2017.07.031_bib0100","first-page":"635","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-Based guidelines for determination of sample size and interpretation of the european organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0110","first-page":"1753","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0115","unstructured":"European Medicines Agency, European Public Assessment Report (EPAR) summary for the public for Iressa (gefitinib), (2009). EMEA\/280173\/2009."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0120","series-title":"Krebs in Deutschland 2011\/2012, 10","year":"2015"},{"key":"10.1016\/j.lungcan.2017.07.031_bib0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0135","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2004.02.109","article-title":"Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer","volume":"22","author":"Hotta","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2007.03.014","article-title":"A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer","volume":"57","author":"Jiang","year":"2007","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0145","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"CISCA (cisplatin versus carboplatin) meta-analysis group, cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2015.11.022","article-title":"Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: analysis from the European FRAME study","volume":"92","author":"Smit","year":"2016","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.lungcan.2012.09.001","article-title":"Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME)","volume":"78","author":"Schnabel","year":"2012","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0160","first-page":"223","article-title":"Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?","volume":"4","author":"Sellmann","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0170","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.031_bib0175","first-page":"19","article-title":"Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy\u2014would patients agree?","volume":"3","author":"Popat","year":"2014","journal-title":"Ann. Palliat. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T22:09:20Z","timestamp":1635631760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217304191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"alternative-id":["S0169500217304191"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.031","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer \u2013 final results from the prospective German TLK cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}